Loading clinical trials...
Loading clinical trials...
A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination With HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis.
Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.
25 adult subjects with moderate to severe plaque psoriasis will receive Ilumya 100mg subcutaneously at weeks 0, 4 and 16. At week 16, patients with remaining BSA ˃3% will be given HALOG ointment 0.1% to apply BID for 4 weeks. Patients who have ≤3% BSA at week 16 will remain on Ilumya monotherapy. Patients will continue to be evaluated at weeks 20 and 24.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey, United States
Start Date
April 6, 2020
Primary Completion Date
December 30, 2020
Completion Date
March 1, 2021
Last Updated
April 15, 2020
25
ESTIMATED participants
Ilumya Injectable Product
DRUG
Lead Sponsor
Psoriasis Treatment Center of Central New Jersey
Collaborators
NCT07449234
NCT07116967
NCT07250802
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions